Amylyx Pharmaceuticals garners $30m Series B

Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc., a developer of new treatments for amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases, has raised $30 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this